301 related articles for article (PubMed ID: 28154176)
1. A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation.
Yin G; Kistler S; George SD; Kuhlmann N; Garvey L; Huynh M; Bagni RK; Lammers M; Der CJ; Campbell SL
J Biol Chem; 2017 Mar; 292(11):4446-4456. PubMed ID: 28154176
[TBL] [Abstract][Full Text] [Related]
2. Allosteric Regulation of Switch-II Domain Controls KRAS Oncogenicity.
Yang MH; Tran TH; Hunt B; Agnor R; Johnson CW; Shui B; Waybright TJ; Nowak JA; Stephen AG; Simanshu DK; Haigis KM
Cancer Res; 2023 Oct; 83(19):3176-3183. PubMed ID: 37556505
[TBL] [Abstract][Full Text] [Related]
3. The molecular basis for immune dysregulation by the hyperactivated E62K mutant of the GTPase RAC2.
Arrington ME; Temple B; Schaefer A; Campbell SL
J Biol Chem; 2020 Aug; 295(34):12130-12142. PubMed ID: 32636302
[TBL] [Abstract][Full Text] [Related]
4. RAS ubiquitylation modulates effector interactions.
Thurman R; Siraliev-Perez E; Campbell SL
Small GTPases; 2020 May; 11(3):180-185. PubMed ID: 29185849
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic aspects of signaling through Ras in NIH 3T3 cells.
Zhang K; Papageorge AG; Lowy DR
Science; 1992 Jul; 257(5070):671-4. PubMed ID: 1496380
[TBL] [Abstract][Full Text] [Related]
6. Direct inhibition of oncogenic KRAS by Bacillus pumilus ribonuclease (binase).
Ilinskaya ON; Singh I; Dudkina E; Ulyanova V; Kayumov A; Barreto G
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1559-67. PubMed ID: 27066977
[TBL] [Abstract][Full Text] [Related]
7. A dominant negative RAS-specific guanine nucleotide exchange factor reverses neoplastic phenotype in K-ras transformed mouse fibroblasts.
Bossù P; Vanoni M; Wanke V; Cesaroni MP; Tropea F; Melillo G; Asti C; Porzio S; Ruggiero P; Di Cioccio V; Maurizi G; Ciabini A; Alberghina L
Oncogene; 2000 Apr; 19(17):2147-54. PubMed ID: 10815806
[TBL] [Abstract][Full Text] [Related]
8. KRAS K104 modification affects the KRAS
Chen CC; Hsu CY; Lin HY; Zeng HQ; Cheng KH; Wu CW; Tsai EM; Hsieh TH
Sci Rep; 2020 Oct; 10(1):17447. PubMed ID: 33060649
[TBL] [Abstract][Full Text] [Related]
9. Insights into K-Ras 4B regulation by post-translational lysine acetylation.
Knyphausen P; Lang F; Baldus L; Extra A; Lammers M
Biol Chem; 2016 Oct; 397(10):1071-85. PubMed ID: 27176741
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of the atypical activation mechanism of KRAS
Bera AK; Lu J; Wales TE; Gondi S; Gurbani D; Nelson A; Engen JR; Westover KD
J Biol Chem; 2019 Sep; 294(38):13964-13972. PubMed ID: 31341022
[TBL] [Abstract][Full Text] [Related]
12. Raf-1 is involved in the regulation of the interaction between guanine nucleotide exchange factor and Ha-ras. Evidences for a function of Raf-1 and phosphatidylinositol 3-kinase upstream to Ras.
Giglione C; Parmeggiani A
J Biol Chem; 1998 Dec; 273(52):34737-44. PubMed ID: 9856997
[TBL] [Abstract][Full Text] [Related]
13. Conformational resolution of nucleotide cycling and effector interactions for multiple small GTPases determined in parallel.
Killoran RC; Smith MJ
J Biol Chem; 2019 Jun; 294(25):9937-9948. PubMed ID: 31088913
[TBL] [Abstract][Full Text] [Related]
14. Probing the GTPase cycle with real-time NMR: GAP and GEF activities in cell extracts.
Marshall CB; Meiri D; Smith MJ; Mazhab-Jafari MT; Gasmi-Seabrook GM; Rottapel R; Stambolic V; Ikura M
Methods; 2012 Aug; 57(4):473-85. PubMed ID: 22750304
[TBL] [Abstract][Full Text] [Related]
15. Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by
Sharma AK; Pei J; Yang Y; Dyba M; Smith B; Rabara D; Larsen EK; Lightstone FC; Esposito D; Stephen AG; Wang B; Beltran PJ; Wallace E; Nissley DV; McCormick F; Maciag AE
J Biol Chem; 2024 Feb; 300(2):105650. PubMed ID: 38237681
[TBL] [Abstract][Full Text] [Related]
16. Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor.
Bustelo XR; Suen KL; Leftheris K; Meyers CA; Barbacid M
Oncogene; 1994 Aug; 9(8):2405-13. PubMed ID: 8036025
[TBL] [Abstract][Full Text] [Related]
17. Electrostatic control of GTP and GDP binding in the oncoprotein p21ras.
Muegge I; Schweins T; Langen R; Warshel A
Structure; 1996 Apr; 4(4):475-89. PubMed ID: 8740369
[TBL] [Abstract][Full Text] [Related]
18. The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS.
Li C; Vides A; Kim D; Xue JY; Zhao Y; Lito P
Science; 2021 Oct; 374(6564):197-201. PubMed ID: 34618566
[TBL] [Abstract][Full Text] [Related]
19. A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers.
Cheng R; Li F; Zhang M; Xia X; Wu J; Gao X; Zhou H; Zhang Z; Huang N; Yang X; Zhang Y; Shen S; Kang T; Liu Z; Xiao F; Yao H; Xu J; Yan C; Zhang N
Cell Res; 2023 Jan; 33(1):30-45. PubMed ID: 36241718
[TBL] [Abstract][Full Text] [Related]
20. Functional characterisation of a novel class of in-frame insertion variants of KRAS and HRAS.
Eijkelenboom A; van Schaik FMA; van Es RM; Ten Broek RW; Rinne T; van der Vleuten C; Flucke U; Ligtenberg MJL; Rehmann H
Sci Rep; 2019 Jun; 9(1):8239. PubMed ID: 31160609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
